Epstein-Barr virus replication and transcription activator (BZLF1)

The Epstein-Barr virus (EBV) BZLF1 protein, also known as ZEBRA or Zta, is a pivotal immediate-early transcription factor that serves as the molecular switch for EBV to transition from its latent phase to the lytic replication cycle (UniProt P03206; PMCID: PMC3312153). By binding to specific Z-responsive elements (ZREs) on the viral genome, BZLF1 initiates the expression of early viral genes and recruits the viral DNA polymerase complex, which is essential for viral genome amplification (PubMed: 25142595). In the context of oncology, BZLF1 is a primary target for 'lytic induction therapy,' a strategy where HDAC inhibitors or other epigenetic modifiers are used to force the virus into the lytic phase within EBV-associated tumor cells (PubMed: 32906140). This induction makes the tumor cells susceptible to antiviral prodrugs like ganciclovir, which are converted into toxic metabolites only in cells undergoing active viral replication, leading to selective cell death (PMCID: PMC7460023). Beyond its role in replication, BZLF1 interacts with various host cellular pathways, including p53 and NF-kappaB, to modulate the cellular environment in favor of viral production (PubMed: 11462002).

Other names

ZEBRAZtaEB1ZBZLF1 protein

Induction of the viral lytic cycle (lytic induction therapy) to sensitize EBV-positive tumor cells to antiviral drugs like ganciclovir.